We will reopen at noon Sunday Sept. 21, 2014
Books by Subject
- 3D cell-based biosensors in drug discovery programs — Drug and biological development (100)
- Drug delivery systems — Microdialysis in drug development (100)
- Modern anesthetics — Razoxane and dexrazoxane (100)
- Reducing mortality in the perioperative period — What your patients need to know about psychiatric medications (37)
PharmacologyAccess restricted to Stanford unless otherwise noted
- 3D cell-based biosensors in drug discovery programs 2010, CRCnetBASE"This book is based upon cutting-edge research conducted in the authors lab (Cellular Bioengineering), which over the past decade has developed a number of sophisticated techniques to facilitate use of 3D cell based assays or biosensors. This book uses data from peer-reviewed publications to conclusively justify use of 3D cell cultures in cell-based biosensors (assays) for (HTS). The majority of assays performed in accelerated drug discovery processes are biochemical in nature, but there is a growing demand for live cell-based assays. Unlike biochemical ones, cellular assays are functional approximations of in vivo biological conditions and can provide more biologically relevant information"--Provided by publisher.
- 5-HT2C receptors in the pathophysiology of CNS disease 2011, Springer
- A to Z drug facts Ovid
- AAPS advances in the pharmaceutical sciences series v. 1-, 2011-, Springer
- AccessMedicine Lange Case files AccessMedicineClinical cases selected from the LANGE Case Files series, edited by Eugene C. Toy, MD.
- Adaptive design methods in clinical trials. 2nd ed. 2012, CRCnetBASEProtocol amendment -- Adaptive randomization -- Adaptive hypotheses -- Adaptive dose-escalation trials -- Adaptive group sequential design -- Statistical tests for adaptive seamless designs -- Adaptive sample size adjustment -- Two-stage adaptive design -- Adaptive treatment switching -- Bayesian approach -- Biomarker adaptive trials -- Target clinical trials -- Sample size and power estimation -- Clinical trial simulation -- Regulatory perspectives : a review of FDA draft guidance.
- Adrenergic receptors 2006, Springer
- Despite the advances in conventional, and novel agent and high dose chemotherapy, multiple myeloma remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in multiple myeloma focusing on the development of molecularly-based novel targeted single-agent and combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. This volume will focus on biology of multiple myeloma, especially on oncogenomic changes, cell signaling pathways and intermediate molecules that are being investigated for development of novel therapies. The book will present newer developments, providing an emphasis on basic science, as well as its significant clinical impact.
- Advances in biology and therapy of multiple myeloma Volume 2, Translational and clinical research 2013, SpringerDespite the advances in conventional, and novel agent and high dose chemotherapy, multiple myeloma remains incurable. In order to overcome resistance to current therapies and improve patient outcome, novel biologically-based treatment approaches are being developed. Current translational research in multiple myeloma focusing on the development of molecularly-based novel targeted single-agent and combination therapies has great promise to achieve high frequency and durable responses in the majority of patients. This volume will focus on biology of multiple myeloma, especially on oncogenomic changes, cell signaling pathways and intermediate molecules that are being investigated for development of novel therapies. The book will present newer developments, providing an emphasis on basic science, as well as its significant clinical impact.
- Adverse drug reactions 2010, SpringerPt. 1. Target organ toxicity. -- Drug-induced liver injury / Michael Holt, Cynthia Ju.-- Drug herpersensitivity reactions involving skin / Oliver Hausmann, Benno Schnyder, Werner J. Pichler.-- Adverse drug reactions affecting blood cells / Richard H. Aster.-- Molecular mechanisms of adverse drug reactions in cardiac tissue / Reza Tabrizchi.-- Mechanisms of drug-induced nephrotoxicity / Thomas D. Nolin, Jonathan Himmelfarb.-- Receptor- and reactive intermediate-mediated mechanisms of teratogenesis / Peter G. Wells, Crystal J.J. Lee, Gordon P. McCallum, Julia Perstin, Patricia A. Harper.-- Pt. II. Mediators/Biochemical pathways.-- Role of reactive metabolites in drug-induced hepatotoxicity / A.M. Srivastava, J. L. Maggs, D. J. Antoine, D. P. Williams, D. A. Smith, B. K. Park.-- Role of cytokines in the mechanism of adverse drug reactions / Mary Jane Masson, Lindsay A. Collins, Lance R. Poh.-- Keap1-Nrf2 cellular defense pathway: mechanisms of regulation and role in protection against drug-induced toxicity / Ian M. Copple, Christopher E. Goldring, Neil R. Kitteringham, B. Kevin Park.-- Signal transduction pathways involved in drug-induced liver injury / Derick Han, Mie Shinohara, Maria D. Ybanez, Behnam Saberi, Neil Kaplowitz.-- Mictrochondrial involvement in drug-induced liver injury / Dominique Pessayre, Abdellah Mansouri, Alain Berson, Bernard Fromenty.-- Pt. III. Examples/Models.-- Mechanisms of acetaminophen-induced liver necrosis / Jack A. Hinson, Dean W. Roberts, Laura P. James.-- Drug-induced liver injury in humans: the case of Ximelagtran / M. Keisu, T.B. Andersson.-- Troglitazone / Tsuyoshi Yokoi.-- Neviropine hypersensitivity / M. Popovic, J.M. Shenton, J. Chen, A. Baban, T. Tharmanathan, B. Mannargudi, D. Abdulla, J.P. Uetrecht.-- Mechanisms of adverse drug reactions to biologics / Janet B. Clarke.-- Pt. IV. Risk factors/Screening drug candidates.-- Pharmacogenetics of idiosyncratic adverse drug reactions / Munir Pirmohamed.-- Danger hypothesis applied to idiosyncratic drug reactions / Jinze Li, Jack P. Uetrecht.-- Approaches for minimizing metabolic activation of new drug candidates in drug discovery / Sanjeev Kumar, Kaushik Mitra, Kelem Kassahun, Thomas A. Baillie.
- pt. I. Continuing medical education -- 1. Can I Think what I Read? / Philip D. Lumb -- pt. II. Clinical pharmacology -- 2. Pharmacological Manipulation in ICU / Daniel De Backer, Katia Donadello and Sabino Scolletta -- pt. III. Kidney -- 3. Renal Injury / Vladimir Gašparović, Ivan Gornik -- pt. IV. Ventilation: adult and paediatric -- 4. Respiratory Mechanics: Principles, Utility and Advances / Alysson R. Carvalho, Walter A. Zin -- 5. Capnometry/capnography in Prehospital Cardiopulmonary Resuscitation / Štefek Grmec, Katia Lah and Štefan Mally -- 6. Weaning from Mechanical Ventilation / Irene Cortés Puch, Andrés Esteban -- 7. Ventilatory Strategies in Acute Lung Injury / Edoardo Calderini, Sara Sher and Eleonora Allegritti -- 8. Mechanical Ventilation Beyond the PICU / Giancarlo Ottonello, Alessia Franceschi -- pt. V. Cardiovascular monitoring 9. The Nexfin Monitor--A Totally Non-Invasive Cardiac Output Monitor / Azriel Perel, Wilbert Wesselink and Jos Settels -- 10. Doppler Echocardiography in ICU Patients: Does It Improve Outcome? / Jan Poelaert -- pt. VI. Management of cardiac arrest -- 11. Mild Therapeutic Hypothermia after Cardiac Arrest / Tommaso Pellis, Vincenzo Mione and Willy P. Mercante -- 12. Nasopharyngeal Cooling During Cardiopulmonary Resuscitation / Francesco Fumagalli, Giuseppe Ristagno -- 13. Amplitude Spectrum Area as a Predictor of Successful Defibrillation / Giuseppe Ristagno, Yongqin Li, Antonino Gullo and Joe Bisera --pt. VII. Advances in experimental and clinical research -- 14. Physiopathology and Severity of Post-Resuscitation Myocardial Dysfunction: Effects of Sodium-Hydrogen Exchanger Isoform-1 (NHE-1) Inhibitors and Erythropoietin / Raúl J. Gazmuri, Iyad M. Ayoub and Jeejabai Radhakrishnan -- 15. Experimental Treatment for Preservation of Mechanically Competent Cardiac Activity Following Cardiac Arrest / Iyad M. Ayoub, Jeejabai Radhakrishnan and Raúl J. Gazmuri -- 16. Erythropoietin Facilitates Return of Spontaneous Circulation and Survival in Victims of Out-of-Hospital Cardiac Arrest / Štefek Grmec, Matej Strand and Raúl J. Gazmuri -- pt. VIII. Infections, sepsis and organ dysfunctions -- 17. Pathophysiology of Resistance amongst Aerobic Gram-negative Bacilli in Particular Acinetobacter Species / Nia Taylor, Luciano Silvestri and Hendrick K.F. Van Saene -- 18. What Have We Learned from the Surviving Sepsis Campaign? / Jean-Louis Vincent, Katia Donadello and Leonardo Gottin -- 19. Source Control / Gabriele Sganga, Valerio Cozza -- 20. Immunoglobulins in Sepsis / Giorgio Berlot, Claudio M. Vassallo and Nicola Busetto -- pt. IX. Perioperative medicine -- 22. Perioperative Medicine--An Introduction / Antonino Gullo, Chiara M. Celestre, Annalaura Paratore and Fortunato Stimoli -- 23. Neuraxial Analgesia for Caesarean and Vaginal Delivery and Childhood Learning Disabilities / Juraj Sprung, Randall Flick and David Warner -- 24. Off-label Drugs in Perioperative Medicine: Clonidine / Cesare Gregoretti, Paolo Pelosi -- pt. X. Spinal cord stimulation -- 25. Cost Effectiveness of Spinal Cord Stimulation in the Management of Severe Angina / Mats Börjesson, Clas Mannheimer -- pt. XI. Neurotrauma -- 26. Clinical Assessment and Diagnostic Procedures in Neurotrauma / Marco Zanello, Matteo Vincenzi and Marco Bandini -- pt. XII. Disaster medicine -- 27. Disaster Preparedness / Francesco Della Corte, Pier Luigi Ingrassia -- 28. Medical Emergency Response in Toxicological Mass Casualty / Pier Luigi Ingrassia, Luca Ragazzoni and Francesco Della Corte -- pt. XIII. Quality of care -- 29. Telemedicine to Improve Care in the Critically Ill / Gastón Murias, Bernat Sales Lluis Blanch -- 30. Professionalism, Quality of Care and Pay-for-Performance Services / Antonino Gullo, Cristina Santonocito, Paolo Murabito and Marinella Astuto.
- Anthocyanins in health and disease 2014, CRCnetBASE
- Antibiotic discovery and development 2012, Springer
- Antibiotic resistance 2012, SpringerIntroduction to antibiotic resistance/ Richard Bax, David Griffin -- The origins of antibiotic resistance/ Gerard D. Wright -- Surveillance programmes and antibiotic resistance: worldwide and regional monitoring of antibiotic resistance trends/ Stephen Hawser -- Current and future challenges in the development of antimicrobial agents/ Robert P. Rennie -- The role of the outer membrane of gram-negative bacteria in antibiotic resistance: Ajax' shield or Achilles' heel?/ Malcolm G.P. Page -- Prevention of drug resistance by combined drug treatment of tuberculosis/ Denis A. Mitchison -- Nonmultiplying bacteria are profoundly tolerant to antibiotics / Yanmin Hu, Anthony Coates -- Persister cells: molecular mechanisms related to antibiotic tolerance / Kim Lewis -- Antimicrobial textiles / J. Vaun McArthur, R.C. Tuckfield, C. Baker-Austin -- Efflux: how bacteria use pumps to control their microenvironment / E. David G. McIntosh -- Antibiotics in phase II and III clinical trials / Anthony R.M. Coates, Gerry Halls.
- Antibiotics in laboratory medicine. 5th ed. 2005, OvidThe breakpoint / Matthew A. Wikler, Paul G. Ambrose -- Antimicrobial susceptibility on solid media / John D. Turnidge, Jan M. Bell -- Susceptibility testing of antimicrobials in liquid media / Daniel Amsterdam -- Antimicrobial susceptibility testing of anaerobic bacteria / David W. Hecht -- Antimycobacterial agents: in vitro susceptibility testing and mechanisms of action and resistance / Clark B. Inderlied and Kevin A. Nash -- Antifungal drugs: mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biological fluids / Michael A. Pfaller, Daniel J. Diekema, and Michael G. Rinaldi -- Antimicrobial susceptibility testing for some atypical microorganisms (chlamydia, mycoplasma, rickettsia, ehrlichia, coxiella, and spirochetes) / Jean-Marc Rolain, Didier Raoult -- Applications, significance of, and methods for the measurement of antimicrobial concentrations in human body fluids / Roger D. Klein and Stephen C. Edberg -- Antimicrobial combinations / Satish K. Pillai, Robert C. Moellering, Jr., and George M. Eliopoulos --Genetic and biochemical mechanisms of bacterial resistance to antimicrobial agents / Louis B. Rice and Robert A. Bonomo -- Molecular methods for the detection of antibacterial resistance genes / Margareta Ieven -- Molecular mechanisms of action for antimicrobial agents: general principles and mechanisms for selected classes of antibiotics / Charles W. Stratton -- The antivirogram and the modes of action of antiviral agents, HIV, hepatitis, influenza, and cytomegalovirus / Pierre Dellamonica ... [et al.] -- Disinfectants and antiseptics, modes of action, mechanisms of resistance, and testing / Joseph M. Ascenzi, Martin S. Favero -- Evaluation of antimicrobials in experimental animal infections / Terry O' Reilly ... [et al.] -- Extravascular antimicrobial distribution and the respective blood and urine concentrations in humans / David M. Bamberger ... [et al.] -- Epidemiology of antimicrobial resistance: species prevalence, susceptibility profiles, and resistance trends / Thomas R. Fritsche, Helio S. Sader, Ronald N. Jones.
- Antibiotics-- the perfect storm 2010, Springer
- Antibody-drug conjugates and immunotoxins 2013, SpringerThe concept of delivering 'magic bullets' to treat diseases was first proposed by Paul Erlich in the early 1900's. The realization of this concept for the treatment of cancer occurred in the late 1990's with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer.
- Anticancer agents from natural products. 2nd ed. 2012, CRCnetBASE"This book covers clinically used anticancer agents that are either natural products or are clearly derived from natural product leads. The second edition includes drugs that are currently in development. In addition, the text emphasizes the applications of synthetic and medicinal chemistry to the preparation of analogs with enhanced activities. Contributors also address the potential of novel drug discovery through the use of genome mining as well as the status of advanced development candidates. For each compound of class of compounds, the text provides information on the history, structure, mechanism of action, development, synthesis, medicinal chemistry, and clinical applications"-- Provided by publisher."The search for new lead compounds is a crucial element of modern pharmaceutical research. Natural products provided the only source of pharmaceuticals for thousands of years, and natural products have made enormous contributions to human health through compounds such as quinine, morphine, aspirin (a natural product analog), digitoxin, and many others. The potential of natural products as anticancer agents was recognized in the 1950's by the U. S. National Cancer Institute (NCI) under the leadership of the late Dr. Jonathan Hartwell, and the NCI has since made major contributions to the discovery of new naturally occurring anticancer agents through its contract and grant support, including an important program of plant and marine collections. Many, although not all, of the compound classes described in the following pages owe their origin in whole or in part to NCI support. In spite of the success of the natural products approach to anticancer drug discovery, as exemplified by the following chapters, in recent years their importance as a source of molecular diversity for drug discovery research and development has been overshadowed by newer chemical approaches currently in favor. These approaches include chemical ones which make heavy use of combinatorial chemistry, and biological ones such as manipulation of biosynthetic pathways of microbial metabolites through combinatorial biosynthetic techniques. It is thus worthwhile to review briefly the major reasons why natural products are so important. First, there is a strong biological and ecological rationale for plants and marine invertebrates to produce novel bioactive secondary metabolites"-- Provided by publisher.
- Anticoagulants, antiplatelets, and thrombolytics 2004, Springer Protocols
- Antimicrobial chemotherapy. 6th ed. / 2012, OvidPt. 1. General properties of antimicrobial agents -- Pt. 2. Resistance to antimicrobial agents -- Pt. 3. General principles of usage of antimicrobial agents -- Pt. 4. Therapeutic use of antimicrobial agents.
- Antiplatelet agents 2012, SpringerPart 1.Pathophysiology.Platelets: Production, Morphology and Ultrastructure /Jonathan N. Thon and Joseph E. Italiano --Platelet Receptors /Alexandre Kauskot and Marc F. Hoylaerts --Platelet Signaling /Timothy J. Stalker, Debra K. Newman, Peisong Ma, Kenneth M. Wannemacher and Lawrence F. Brass --Platelet Interaction with the Vessel Wall /Philip G. de Groot, Rolf T. Urbanus and Mark Roest --Platelets in Atherosclerosis and Thrombosis /Christian Schulz and Steffen Massberg --Part 2.Pharmacology.Aspirin and Other COX-1 Inhibitors /Carlo Patrono and Bianca Rocca --Thienopyridines and Other ADP-Receptor Antagonists /Isabell Bernlochner and Dirk Sibbing --Glycoprotein IIb/IIIa Antagonists /Karen M. Hook and Joel S. Bennett --Targeting Phosphodiesterases in Anti-platelet Therapy /Matthew T. Rondina and Andrew S. Weyrich --PAR-1 Inhibitors: A Novel Class of Antiplatelet Agents for the Treatment of Patients with Atherothrombosis /Sergio Leonardi and Richard C. Becker --Thromboxane Receptors Antagonists and/or Synthase Inhibitors /Giovanni Davì, Francesca Santilli and Natale Vazzana --Inhibitors of the Interaction Between von Willebrand Factor and Platelet GPIb/IX/V /Paolo Gresele and Stefania Momi --Inhibitors of the Interactions Between Collagen and Its Receptors on Platelets /Hans Deckmyn, Simon F. De Meyer, Katleen Broos and Karen Vanhoorelbeke --Intracellular Signaling as a Potential Target for Antiplatelet Therapy /Patrick Andre --Novel Targets for Platelet Inhibition /Kathleen Freson and Chris Van Geet --Variability of Platelet Indices and Function: Acquired and Genetic Factors /Giovanni de Gaetano, Iolanda Santimone, Francesco Gianfagna, Licia Iacoviello and Chiara Cerletti --Small RNAs as Potential Platelet Therapeutics /Leonard C. Edelstein and Paul F. Bray --Pharmacological Modulation of the Inflammatory Actions of Platelets /Richard Amison, Clive Page and Simon Pitchford --Part 3.Therapy.The Role of Laboratory Monitoring in Antiplatelet Therapy /Marco Cattaneo --Antiplatelet Agents in Ischemic Heart Disease /Christopher H. May and A. Michael Lincoff --Antiplatelet Therapy in Cerebrovascular Disorders /Ralph Weber, Johannes Brenck and Hans-Christoph Diener --Antiplatelet Therapy in Peripheral Artery Disease /Francesco Violi, Stefania Basili, Jeffrey S. Berger and William R. Hiatt --Primary Prevention of Ischaemic Cardiovascular Disorders with Antiplatelet Agents /Tom Mead.
- Antisense drug technology. 2nd ed. 2008, CRCnetBASEMechanisms of antisense drug action, an introduction / Stanley T. Crooke ... [et al.] -- The RNase H mechanism / Walt Lima, Hongjiang Wu, and Stanley T. Crooke -- Small RNA silencing pathways / Alla Sigova and Phillip D. Zamore -- Splice switching oligonucleotides as potential therapeutics / Peter Sazani, Maria A. Graziewicz, and Ryszard Kole -- Basic principles of antisense drug discovery / Susan M. Freier and Andrew T. Watt -- The medicinal chemistry of oligonucleotides / Eric E. Swayze and Balkrishen Bhat -- Basic principles of the pharmacokinetics of antisense oligonucleotide drugs / Arthur A. Levin, Rosie Z. Yu, and Richard S. Geary -- Routes and formulations for delivery of antisense oligonucleotides / Gregory E. Hardee, Lloyd G. Tillman, and Richard S. Geary -- Liposomal formulations for nucleic acid delivery / Ian MacLachlan -- Pharmacological properties of 2'-O-methoxyethyl-modified oligonucleotides / C. Frank Bennett -- Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man / Richard S. Geary ... [et al.] -- Toxicologic properties of 2'-O-methoxyethyl chimeric antisense inhibitors in animals and man / Scott P. Henry ... [et al.] -- An overview of the clinical safety experience of first- and second-generation antisense oligonucleotides / T. Jesse Kwoh -- Manufacturing and analytical processes for 2'-O-(2-methoxyethyl)-modified oligonucleotides / Daniel C. Capaldi and Anthony N. Scozzari -- Utilizing chemistry to harness RNA interference pathways for therapeutics : chemically modified siRNAs and antagomirs / Muthiah Manoharan and Kallanthottathil G. Rajeev.Discovery and development of RNAi therapeutics / Antonin R. deFougerolles and John M. Maraganore -- Optimization of second-generation antisense drugs: going beyond generation 2.0 / Brett P. Monia ... [et al.] -- Modulating gene function with peptide nucleic acids (PNA) / Peter E. Nielsen -- Locked nucleic acid / Troels Koch and Henrik Ørum -- Morpholinos / Patrick L. Iversen -- Potential therapeutic applications of antisense oligonucleotides in ophthalmology / Lisa R. Grillone and Scott P. Henry -- Cardiovascular therapeutic applications / Rosanne M. Crooke, Brenda Baker, and Mark Wedel -- Developing antisense drugs for metabolic diseases: a novel therapeutic approach / Sanjay Bhanot -- Inflammatory diseases / Susan A. Gregory and James G. Karras -- Antisense oligonucleotides for the treatment of cancer / Boris A. Hadaschik and Martin E. Gleave -- Targeting neurological disorders with antisense oligonucleotides / Richard A. Smith and Timothy M. Miller -- Mechanisms and therapeutic applications of immune modulatory oligodeoxynucleotide and oligoribonucleotide ligands for toll-like receptors / Jörg Vollmer and Arthur M. Krieg -- Aptamer opportunities and challenges / Charles Wilson.
- Antisense therapeutics. 2nd ed. 2005, Springer ProtocolsAntisense therapeutics: a promise waiting to be fulfilled / M. Ian Phillips -- Antisense inhibition: oligonucleotides, ribozymes and siRNAs / Y. Clare Zhang ... [et al.] -- Local application of antisense for prevention of restenosis / Patrick L. Iversen ... [et al.] -- Antisense therapeutics for hypertension: targeting the renin-angiotensin system / M. Ian Phillips and Birgitta Kimura -- Antisense strategies for the treatment of heart failure / Sian E. Harding, Federica del Monte, and Roger J. Hajjar -- Clinical studies of antisense oligonucleotides for cancer therapy / Rosanne M. Orr and F. Andrew Dorr -- Antisense therapy in clinical oncology: preclinical and clinical experiences / Ingo Tamm -- Radionucleide-peptide nucleic acid diagnosis and treatment of pancreatic cancer / Eric Wickstrom ... [et al.] -- Suppression of pancreatic and colon cancer cells by antisense K-ras RNA expression vectors / Kazunori Aoki, Shumpei Ohnami, and Teruhiko Yoshida -- Induction of tumor cell apoptosis and chemosensitization by antisense strategies / Manuel Rieber and Mary Strasberg-Rieber -- Utility of an anti-oncogene ribozymes and antisense oligonucletoides in reversing drug resistance / Tadao Funato -- Transport of antisense across the blood-brain barrier / Laura B. Jaeger and William A. Banks -- Transdermal delivery of antisense oligonucletoides / Rhonda M. Brand and Patrick L. Iversen -- Antisense strategies for redirection of drug metabolism: using paclitaxel as a model / Vikram Arora -- Antisense oligonucletoide treatment of inflammatory bowel diseases / Bruce R. Yacyshyn -- Optimizing electroporation conditions for the intracellular delivery of morpholino antisense oligonucleotides directed against the hepatitis C virus internal ribosome entry site / Ronald Jubin.
- The modern unhealthy diet and lifestyle in conjunction with pathogens, environmental carcinogens and multiple other risk factors increase humans' susceptibility to different diseases exemplified by elevated levels of cancers, cardiovascular and communicable diseases. Screening of potential drugs from medicinal plants and animals provides a promising strategy for the alleviation of the impact of these diseases. Components with potential medicinal applications include RIPs, RNases, lectins, protease inhibitors and numerous small compounds. These compounds have shown both preventive and therapeutic effects for humans. This book is a compilation of articles written by internationally renowned experts exploring the different uses of medicinal compounds in human therapeutics. Here we provide a comprehensive outlook on both qualitative and quantitative studies focusing on medicinal plants and animals, and establishing a link between laboratory research discovery and clinical applications.
- Antiviral strategies 2009, Springer
- Appetite control 2012, SpringerThe volume Appetite Control provides a comprehensive description of the mechanisms controlling food intake, and thereby energy balance, in the mammalian organism. During the last decade, research in this area has produced a remarkable wealth of information and has characterized the function of numerous peptides, transmitters, and receptors in appetite control. Dysfunction of these circuits leads to obesity, a growing health concern. However, the plethora of mechanistic information is in marked contrasts to an almost complete lack of anti-obesity drugs that meet the safety standards required for the chronic therapy of morbid obesity. Consequently, ongoing research aims to identify additional targets and agents for a pharmacological intervention. Thus, the mechanisms of appetite control as well as all agents interfering with its control are of considerable practical interest.The authors of the volume are distinguished scientists who are leading experts in the field, and who have contributed important, original data to our understanding of the mechanisms of appetite control. They have quite different scientific backgrounds and, together, they represent all relevant disciplines. Thereby, the topics are presented from different points of view, not exclusively from that of pharmacology and neuroendocrinology. Thus, the volume addresses all scientists who are interested in the field of obesity research and the pathophysiology of appetite control.
- Introduction -- Application of prodrug chemistry to GLP-1 -- Experimental procedures -- Characterization of prodrugs -- Conclusion -- Appendix I. Schematic synthesis of longer acting prodrugs -- Appendix II: Structure of peptides in Table A.1 -- Appendix III: Structure of peptides in table A.2 -- Appendix IV: Structure of peptides in table A.3 -- Appendix V: Structure of peptides in table A.4 Appendix VI: Structure of peptides in table A.5 -- Appendix VII. Structure of peptides in table A.6 -- Appendix VIII: Acylataion of HO-His7, GLP(8-37) -- Appendix IX: A note on nomenclature.
- Omics & microarrays revisited -- The commercial microarrays -- Supports & surface chemistries -- The arraying processes -- Gene expression microarray-based applications -- Protein microarray applications -- Multiplex assays.
- Approaches to the conformational analysis of biopharmaceuticals 2010, CRCnetBASEIntroduction to biopharmaceutical conformational analysis : issues and methods -- Comparability of biotechnological/biological products and biological generics -- Application of native electrophoresis for the study of protein conformation -- Affinity chromatography including hydrophobic interaction chromatography in the study of biopolymer conformation -- Size-exclusion chromatography and bimolecular conformation -- Use of analytical ultracentrifugation to study biomolecular conformation -- Use of differential scanning calorimetry to measure conformational change in proteins and other biomacromolecules -- Light scattering and biomacromolecular conformation -- Use of luminescence to measure conformational change in biopharmaceuticals with emphasis on protein and protein drug products -- Near-infrared spectroscopy and macromolecular conformation -- Use of mid-infrared and Fourier transform infrared spectroscopy to study conformation of biomacromolecules -- Use of Raman spectroscopy to evaluate biopharmaceutical conformation -- The use of UV-VIS spectrophotometry for the characterization of biopharmaceutical products -- Use of optical rotatory dispersion and circular dichroism to study therapeutic biomacromolecule conformation -- Use of nuclear magnetic resonance for the characterization of biotherapeutic products -- Use of chemical probes for the study of protein conformation -- Use of hydrogen exchange in the study of biopharmaceutical conformation -- Use of chemical modification for the conformational analysis of biopharmaceuticals -- Use of immunology to characterize biopharmaceutical conformation -- Use of limited proteolysis to study the conformation of proteins of biotechnological interest -- Other technologies for the characterization of conformational change in biopharmaceuticals -- Development of an experimental approach for the study of the conformation of a biological therapeutic product.
- Appropriate dose selection 2007, Springer
- Arrestins-- Pharmacology and therapeutic potential 2014, SpringerThis volume describes our current understanding of the biological role of visual and non-visual arrestins in different cells and tissues, focusing on the mechanisms of arrestin-mediated regulation of GPCRs and non-receptor signaling proteins in health and disease. The book covers wide range of arrestin functions, emphasizing therapeutic potential of targeting arrestin interactions with individual partners.
- Aspirin and related drugs 2004, CRCnetBASE
- Assessing ocular toxicology in laboratory animals 2013, SpringerOcular toxicity is routinely assessed in toxicology studies conducted for regulatory purposes. Ocular anatomy and physiology and the assessment of ocular toxicity itself can be challenging to scientists involved in the safety assessment of pharmaceuticals, pesticides and other agents. Anatomical and physiological differences between species can impact the nature of ocular effects observed following intended or unintended exposure of ocular tissues to xenobiotics. Ocular Toxicity in Laboratory Animals provides a concise reference addressing ocular anatomy and physiology across species that will enhance the design and interpretation of toxicology studies conducted for regulatory purposes. The book provides an overview of routine and advanced techniques that are used to assess ocular toxicity including slit lamp biomicroscopy, indirect ophthalmoscopy, electrophysiology and imaging methods for the anterior and posterior segments of the eye. Additionally, the book defines the regulatory expectations for pharmaceuticals intended to treat ocular diseases and for other non-pharmaceutical regulated chemicals. With contributions from experts in the field, Ocular Toxicity in Laboratory Animals is an authoritative, accessible guide for toxicologists and other scientists involved in conducting toxicology studies for regulatory purposes and/or reviewing data from such studies.
- Atlas of toxicological pathology 2014, Springer"This atlas contains more than 700 illustrations that the authors have collected over the years as well as references and information pertaining to recently developed drug classes, including biologics. It is a useful bench reference for practicing pathologists and may also be used as a reference text by other experts from related fields. The atlas is organised into different chapters based on systemic pathology. Each chapter has illustrations with legends, and the atlas includes some rare examples of unique lesions found during toxicity studies over many years."--Publisher's website.
- Bacterial resistance to antimicrobials. 2nd ed. 2008, CRCnetBASEMicrobial drug resistance: a historical perspective / William C. Summers -- Ecology of antibiotic resistance genes / Abigail A. Salyers, Nadja Shoemaker, and David Schlesinger -- Global response systems that confer resistance / Paul F. Miller and Philip N. Rather -- Multidrug efflux pumps: structure, mechanism, and inhibition / Olga Lomovskaya ... [et al.] -- Mechanisms of aminoglycoside antibiotic resistance / Gerard D. Wright -- Resistance to [beta]-lactam antibiotics mediated by [beta]-lactamases : structure, mechanism, and evolution / Jooyoung Cha, Lakshmi P. Kotra, and Shahriar Mobashery -- Target modification as a mechanism of antimicrobial resistance / David C. Hooper -- Antibiotic permeability / Harry Taber -- Genetic methods for detecting bacterial resistance genes / Ad C. Fluit --Evolution and epidemiology of antibiotic-resistant pneumococci / Christopher Gerard Dowson and Krzysztof Trzcinski -- Antimicrobial resistance in the enterococcus / George M. Eliopoulos -- Methicillin resistance in staphylococcus aureus / Keeta S. Gilmore, Michael S. Gilmore, and Daniel F. Sahm -- Mechanism of drug resistance in mycobacterium tuberculosis / Alex S. Pym and Stewart T. Cole -- Antibiotic resistance in enterobacteria / Nafsika H. Georgopapadakou -- Resistance as a worldwide problem / Paul Shears -- Public health responses to antimicrobial resistance in outpatient and inpatient settings / Cindy R. Friedman and Arjun Srinivasan -- Antibacterial drug discovery in the 21st century / Steven J. Projan.
- Bacteriocins 2007, Springer
- Basic & clinical pharmacology 2012 (12th ed.)., AccessMedicine
- Biocombinatorial approaches for drug finding 2005, Springer
- Bioequivalence and statistics in clinical pharmacology 2006, CRCnetBASE
- Bioinformatics and drug discovery 2005, Springer ProtocolsNew strategies in drug discovery / Eliot H. Ohlstein ... [et al.] -- Basic microarray analysis: strategies for successful experiments / Scott A. Ness -- From microarray to biological networks: analysis of gene expression profiles / Xiwei Wu and T. Gregory Dewey -- Microarray analysis in drug discovery and clinical applications / Siqun Wang and Qiong Cheng -- Ontology-driven approaches to analyzing data in functional genomics / Francisco Azuje, Fatima Al-Shahrour, and Joaquin Dopazo -- Gene evolution and drug discovery / James O. McInerney ... [et al.] -- Standardization of microarray and pharmacogenomics data / Cassey S. Husser ... [et al.] -- Clinical applications of bioinformatics, genomics, and pharmacogenomics / Omer Iqbal and Jawed Fareed --Protein interactions probed with mass spectrometry / Suma Kaveti and John R. Engen -- Discovering new drug targeting sites on flexible multidomain protein kinases -- combining segmental isotopic and site-directed spin labeling for nuclear magnetic resonance dectection of interfacial clefts / Thomas K. Harris -- Nuclear magnetic resonance-based screening methods for drug discovery / Laurel O. Sillerud and Richard S. Larson -- Receptor binding sites: bioinformatic approaches / Darren R. Flower -- In silico protein design: fitting sequence onto structure / Bassil I. Dahiyat -- Chemical database preparation for compound acquisition or virtual screening / Cristian G. Bologa, Marius M. Olah, and Tudor I. Oprea -- Bioinformatics platform development: from gene to lead compound / Alexis S. Ivanov ... [et al.].
- Biologics in general medicine 2007, Springer
- Biology of marijuana 2002, CRCnetBASE
- Biomarker methods in drug discovery and development 2008, Springer
- Biopharmaceutics applications in drug development 2008, Springer
- Biosimilars 2013, SpringerBiologicals' Characteristics / K. Ho and J.-H. Trouvin --From the Biosimilar Concept to the Marketing Authorisation / M. Pavlovic and J.-L. Prugnaud --Immunogenicity / J.-L. Prugnaud --Substitution and Interchangeability / J.-L. Prugnaud --G-CSFs: Onco-Hematologist's Point of View / D. Kamioner --The Oncologist's Point of View / C. Chouaïd --Biosimilars: Challenges Raised by Biosimilars: Who is Responsible for Cost and Risk Management? / F. Megerlin.
- Biosimilars 2014, CRCnetBASE"This is the first book entirely devoted to the design and analysis for assessment of biosimilarity and drug interchangeability of biosimilars, and test for comparability in manufacturing processes of biologic products. It covers all of the statistical issues that may occur in biosimilar studies under various study designs at various stages of research and development of biologic products"-- Provided by publisher.
- "... provides an established, recognized, authoritative and comprehensive source on medicinal chemistry and drug discovery and development. This flagship reference for medicinal chemists and pharmaceutical professions has been thoroughly updated and expanded across 8 volumes to incorporate the entire process of drug development (preclinical testing, clinical trials, etc.) alongside the traditional strengths in medicinal chemistry and drug discovery"--Provided by publisher.
- Caffeine and activation theory 2007, CRCnetBASE
- Calcium signaling protocols. 2nd ed. 2005, Springer ProtocolsFluorescent measurement of [Ca²+]c: basic practical considerations / Alec W.M. Simpson -- Measurement of [Ca²+]i in whole cell suspensions using fura-2 / Robert A. Hirst ... [et al.] -- Measurement of [Ca²+]i in cell suspensions using indo-1 / Adriaan Nelemans -- Confocal microscopy: theory and applications for cellular signaling / Stephen C. Tovey, Paul J. Brighton, and Gary B. Willars -- Single-cell and subcellular measurement of intracellular Ca²+ concentration / Anthony J. Morgan and Andrew P. Thomas -- Ratiometric Ca²+ measurements using the FlexStation scanning fluorometer / Ian C.B. Marshall, Izzy Boyfield, and Shaun McNulty -- Measuring Ca²+ changes in multiwell format using the fluorometric imaging plate reader / Ian C.B. Marshall, Davina E. Owen, and Shaun McNulty --Measurement of Ca²+ entry using cells ⁴⁵Ca²+ / Mercedes Villarroya ... [et al.] -- Measurement of [³H]PN200-110 and [¹²⁵I]-conotoxin MVIIA binding / Kazuyoshi Hirota and David G. Lambert -- Whole-cell patch clamp recording of voltage-sensitive Ca²+ channel currents: heterologous expression systems and dissociated brain neurons / Atticus H. Hainsworth, Andrew D. Randall, and Alessandro Stefani -- Measurement of phospholipase C by monitoring inositol phosphates using [³H]inositol-labeling protocols in permeabilized cells / Alison Skippen, Philip Swigart, and Shamshad Cockcroft -- Measurement of inositol(1,4,5)triphosphate using a stereospecific radioreceptor mass assay / Darren Smart --Measurement of calcium fluxes in permeabilized cells using a ⁴⁵Ca²+ uptake and release assay / Robert A. Wilcox -- Microinjection of myo-inositol(1,4,5)trisphosphate and other calcium-mobilizing agents into intact adherent cells / Robert A. Wilcox, Ian D. Forsythe, and Terence J. McCann -- Measurement of free [Ca²+] changes in agonist-sensitive internal stores using compartmentalized fluorescent indicators / Aldebaran M. Hofer -- Measurement of [Ca²+]i in smooth muscle strips using front-surface fluorimetry / Hideo Kanaide -- Measurement of calcium and movement in heart cells / Leong L. Ng and Paulene A. Quinn --Simultaneous analysis of intracellular pH and Ca²+ from cell populations / Raul Martinez-Zaguilan ... [et al.] -- Measurement of cytosolic-free Ca²+ in plant tissue / Martin R. McAinsh and Carl K.-Y. Ng -- Assay and purification of calmodulin-dependent protein kinase / Rajendra K. Sharma -- Assay and purification of calmodulin-dependent cyclic nucleotide phosphodiesterase and isozyme separation / Rajendra K. Sharma -- Measurement of Ca²+-ATPase activity (in PMCA and SERCA1) / Danuta Kosk-Kosicka.
- Cancer immunotherapy 2013, SpringerThis volume is a comprehensive discussion of the major factors affecting tumor immunology and a discussion of all major anti-cancer immunotherapeutic agents approved by the Food and Drug Administration of the United States and by European agencies. Many promising but unapproved agents in clinical trials are also discussed, as are key pre-clinical developments. The major challenges and intellectual issues facing investigators developing novel immunotherapeutics are discussed in detail as are conceptual developments influencing current and future treatment strategies.Each chapter begins by defining all relevant key terms and concepts and provides pertinent background information so that the text will be accessible to newcomers to the field as well as to the expert. This text book should provide an excellent reference resource for investigators in tumor immunology, life sciences students, drug developers designing novel anti-cancer immunotherapeutics, and to other individuals with some scientific training wishing to gain a better understanding of the field of tumor immunotherapy.Although the field is evolving rapidly, we have taken pains to ensure that information was as up to date as possible as the text went to press.
- Cancer immunotherapy meets oncology 2014, SpringerThis book provides a comprehensive update on the state of the art in cancer immunology, which has rapidly evolved from a field of clinical research into an established discipline of oncology. The key recent developments in immuno-oncology are all covered, from the ever-changing immunological and regulatory frameworks to the most promising therapeutic concepts. Themes include combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing. Cancer Immunotherapy Meets Oncology is dedicated to the lifetime achievements of Christoph Huber, founder and chair of the Association for Cancer Immunotherapy (CIMT). It is also a tribute to those researchers and clinicians who are striving to develop novel diagnostics and tailored immunotherapies for the benefit of cancer patients.
- Cannabinoid receptors 2009, Springer
- Cannabinoids 2005, Springer
- Cannabinoids and the brain 2008, Springer
- Cannabinoids as therapeutics 2005, Springer
- Capillary electrophoresis methods for pharmaceutical analysis. 1st ed. 2008, ScienceDirectOverview of Capillary Electrophoresis in Pharmaceutical Analysis -- Theoretical Consideration in Performance of Various Modes of CE -- Equipment Considerations for Capillary Electrophoresis -- Method Development for Pharmaceutical Analysis -- Role of CE in Drug Substance and Drug Product Development -- General Considerations to Improve Performance of CE Methods -- Overview of Current Regulatory Guidance -- Qualification of CE Instrumentation -- Robustness Testing of CE Methods -- Validation of Analytical Methods Using Capillary Electrophoresis-- The Need for CE Methods in Pharmacopeial Monographs -- CE in Impurity Profiling of Drugs -- Ion Analysis Using Capillary Electrophoresis -- Role of CE in Biopharmaceutical Development and Quality Control -- Capillary Electrophoresis and Bioanalysis -- CE as an Orthogonal Technique to Chromatography -- Capillary Electrochromatography of Pharmaceuticals -- Coupling CE and Chip-based Devices and Mass Spectrometry.
- Carbohydrate-based drug discovery 2003, Wileych. 1. Synthetic methodologies / Chikako Saotome, Osamu Kanie -- ch. 2. Complex carbohydrate synthesis / Makoto Kiso, Hideharu Ishida, Hiromune Ando -- ch. 3. The chemistry of sialic acid / Geert-Jan Boons, Alexei V. Demchenko -- ch. 4. Solid-phase oligosaccharide synthesis / Peter H. Seeberger -- ch. 5. Solution and polymer-supported synthesis of carbohydrates / Shin-Ichiro Nishimura -- ch. 6. Enzymatic synthesis of oligosaccharides / Jianbo Zhang, Jun Shao, Prezemk Kowal, Peng George Wang -- ch. 7. Glycopeptides and glycoproteins : synthetic chemistry and biology / Oliver Seitz -- ch. 8. Synthesis of complex carbohydrates : Everninomicin 13,384-1 / K. C. Nicolaou, Helen J. Mitchell, Scott A. Snyder -- ch. 9. Chemical synthesis of asparagine-linked glycoprotein oligosaccharides : recent examples / Yukishige Ito, Ichiro Matsuo -- ch. 10. Chemistry and biochemistry of asparagine-linked protein glycosylation / Barbara Imperiali, Vincent W.-F. Tai -- ch. 11. Conformational analysis of C-glycosides and related compounds : programming conformational profiles of C- and O-glycosides / Peter G. Goekjian, Alexander Wei, Yoshito Kishi -- ch. 12. Synthetic lipid A antagonists for sepsis treatment / William J. Christ, Lynn D. Hawkins, Michael D. Lewis, Yoshito Kishi -- ch. 13. Polysialic acid vaccines / Harold J. Jennings -- ch. 14. Synthetic carbohydrate-based vaccines / Stacy J. Keding, Samuel J. Danishefsky -- ch. 15. Chemistry, biochemistry, and pharmaceutical potentials of glycosaminoglycans and related saccharides / Tasneem Islam, Robert J. Linhardt -- ch. 16. A new generation of antithrombotics based on synthetic oligosaccharides / Maurice Petitou, Jean-Marc Herbert -- ch. 17. Sequencing of oligosaccharides and glycoproteins / Stuart M. Haslam, Kay-Hooi Khoo, Anne Dell -- ch. 18. Preparation of heterocyclic 2-deoxystreptamine aminoglycoside analogues and characterization of their interaction with RNAs by use of electrospray ionization mass spectrometry / Richard H. Griffey, Steven A. Hofstadler, Eric E. Swayze -- ch. 19. Glycosylation analysis of a recombinant P-selectin antagonist by high-pH anion-exchange chromatography with pulsed electrochemical detection (HPAEC/PED) / Mark R. Hardy, Richard J. Cornell -- ch. 20. Analytical techniques for the characterization and sequencing of glycosaminoglycans / Ram Sasisekharan, Zachary Shriver, Mallik Sundaram, Ganesh Venkataraman -- ch. 21. Thermodynamic models of the multivalency effect / Pavel I. Kitov, David R. Bundle -- ch. 22. Synthetic multivalent carbohydrate ligands as effectors or inhibitors of biological processes / Laura L. Kiessling, Jason K. Pontrello, Michael C. Schuster -- ch. 23. Glycosyltransferase inhibitors / Karl-Heinz Jung, Richard R. Schmidt -- ch. 24. RNA-aminoglycoside interactions / Haim Weizman, Yitzhak Tor -- ch. 25. Glycosylated natural products / Jon S. Thorson, Thomas Vogt -- ch. 26. Novel enzymatic mechanisms in the biosynthesis of unusual sugars / Alexander Wong, Xuemei He, Hung-Wen Liu -- ch. 27. Neoglycolipids : identification of functional carbohydrate epitopes / Ten Feizi, Alexander M. Lawson, Wengang Chai -- ch. 28. A preamble to aglycone reconstruction for membrane-presented glycolipid mimics / Murugesapillai Mylvaganam, Clifford A. Lingwood -- ch. 29. Small molecule inhibitors of the sulfotransferases / Dawn E. Verdugo, Lars C. Pedersen, Carolyn R. Bertozzi -- ch. 30. Carbohydrate-based treatment of cancer metastasis / Reiji Kannagi -- ch. 31. N-acetylneuraminic acid derivatives and mimetics as anti-influenza agents / Robin Thomson, Mark Von Itzstein -- ch. 32. Modified and modifying sugars as a new tool for the development of therapeutic agents : the biochemically engineered N-acyl side chain of sialic acid : biological implications and possible uses in medicine / Rüdiger Horstkorte, Oliver T. Keppler, Werner Reutter -- ch.33 . Modified and modifying sugars as a new tool for the development of therapeutic agents : glycosidated phospholipids as a new type of antiproliferative agents / Kerstin Danker, Annette Fischer, Werner Reutter -- ch. 34. Glycoside primers and inhibitors of glycosylation / Jillian R. Brown, Mark M. Fuster, Jeffrey D. Esko -- ch. 35. Carbohydrate-based drug discovery in the battle against bacterial infections : new opportunities arising from programmable one-pot oligosaccharide synthesis / Thomas K. Ritter, Prof. Dr. Chi-Huey Wong.
- Caveolins in cancer pathogenesis, prevention and therapy 2012, Springer1. Local and Distant Effects of Caveolin-1 on Prostate Cancer Progression / T.C. Thompson, S.A. Tahir, L. Li, M. Watanabe, K. Naruishi, G. Yang, Ken-ichi Tabata, S. Kurosaka, K. Edamura, R. Tanimoto, P. Corn, D. Kadmon, C.J. Logothetis, P. Troncoso, C. Ren, A. Goltsov, and S. Park -- 2. Caveolin-1 in Colon Cancer: The Flexible Connection to Wnt Signaling / Andrew F.G. Quest, Vicente A. Torres, Diego A. Rodriguez, Jorge Gutierrez-Pajares, and Julio C. Tapia -- 3. Caveolin-1 and Pancreatic Ductal Adenocarcinoma / David W. Rittenhouse, Oeendree Mukherjee, Nathan G. Richards, Charles J. Yeo, Agnieszka K. Witkiewicz, and Jonathan R. Brody -- 4. Caveolin-1 in Brain Tumors / Rebecca Senetta and Paola Cassoni -- 5. The Role of Caveolin-1 in Skin Cancer -- / Alessandra Carè, Isabella Parolini, Federica Felicetti, and Massimo Sargiacomo -- 6. Caveolins in Tumor Angiogenesis / Grzegorz Sowa -- 7. Caveolin-1 and Breast Cancer / Gloria Bonuccelli and Michael P. Lisanti -- 8. Caveolin-1 and Cancer-Associated Stromal Fibroblasts / Isabelle Mercier and Michael P. Lisanti.
- Cell signaling & molecular targets in cancer 2012, Springer1. GRB2 Signaling as a Molecular Target for Cancer / Alessio Giubellino -- 2. Human Arylamine N-acetyltransferase 1: From Drug Metabolism to Drug Target / Fernando Rodrigues-Lima, Julien Dairou, Florent Busi, and Jean-Marie Dupret -- 3. Targeting Argininosuccinate Synthetase in Cancer Therapy / Niramol Savaraj, Min You, Chunjing Wu, Macus Tien Kuo, Vy Dinh, Medhi Wangpaichitr, and Lynn Feun -- 4. Parathyroid Hormone-Related Peptide Signaling in Cancer / Franco Oreste Ranelletti and Giovanni Monego -- 5. Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma / Francesco Piazza and Gianpietro Semenzato -- 6. Role of Bile Acids in Carcinogenesis of Gastrointestinal Tract / Hiroshi Yasuda and Fumio Itoh -- 7. AIB1: A Transcriptional Coactivator Which Integrates Signaling Cross Talk in Cancer Cells / Macarena Ferrero and Jaime Font de Mora -- 8. Rational Design of DNA Anticancer Agent That Targets Signal Transducer and Activator of Transcription 3 (Stat3) for Cancer Therapy / Naijie Jing -- 9. Estrogen Receptor Signaling in Lung Cancer / P.A. Hershberger and J.M. Siegfried -- 10. Microparticle Dissemination of Biological Activities: Implications for Cancer Biology / Pauline P. Goh -- 11. Protein Kinase D Signaling in Cancer / Peter Storz -- 12. Cell Signaling and Cancer: Integrated, Fundamental Approach Involving Electron Transfer, Reactive Oxygen Species, and Antioxidants / Peter Kovacic and Ratnasamy Somanathan -- 13. Targeting Signal Transducer and Activator of Transcription (STAT) for Anticancer Therapy / Fabio P.S. Santos, Inbal Hazan-Halevy, and Zeev Estrov.
- Challenge of CMC regulatory compliance for biopharmaceuticals and other biologics. Second edition. [2nd ed.] 2013, SpringerAn effective CMC regulatory compliance strategy for biologics and biopharmaceuticals can seem like a mystery. Through means of this 2nd edition, this no longer needs to occur. A great deal of thanks goes to two regulatory authorities - the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), who provide through their respective websites, an abundance of guidance, especially in the last several years. So much has changed since the 1st edition of this book was published in 2004. There are now additional manufacturing processes for producing commercial biopharmaceuticals - transgenic plant cell cultures and transgenic animals. In addition to commercial recombinant proteins and monoclonal antibodies, there are now commercial cell-based medicines (cellular therapy) and DNA-based medicines (gene therapy). Biosimilars are now on the marketplace in Europe, and under review for commercial approval in the USA. Vaccine manufacturing has resurged due to the concerns of potentially pandemic mutated animal influenzas (e.g., swine flu, bird flu). Strategic international regulatory guidances have been adopted that are driving the entire pharmaceutical industry, including biopharmaceuticals, to a higher standard of performance, including Quality by Design (QbD), Quality Risk Management (QRM) and Pharmaceutical Quality Systems (PQS). The vast majority of the over 600 regulatory references listed in this book were either issued or updated since the release of the 1st edition. All of these changes are the reason this updated edition includes not only biopharmaceuticals but also other biologics (e.g., live virus vaccines, human plasma-derived proteins, cell-based medicines, natural-sourced proteins) that have CMC regulatory compliance concerns and challenges in common with the genetically-engineered biologics (i.e., the biopharmaceuticals).
- Part I. Virology, pathogenesis, and clinical and epidemiological features of disease -- Part II. Host response to infection and genetics of disease -- Part III. Vaccine platforms and treatment options -- Part IV. Animal and tissue culture models of infection -- Part V. Conclusions -- Index.
- Challenges for the FDA 2007, NAP
- Chemical and pharmaceutical industry in China 2005, Springer
- Chemistry and pharmacology of anticancer drugs 2006, CRCnetBASEIntroduction to cancer -- Antimetabolites -- DNA-interactive agents -- Antitubulin agents -- Cell signaling inhibitors -- Hormonal therapies -- Tumour targeting strategies -- Biologicals -- The future -- Personalized medicine (oncogenomics) -- Adjunct therapies.
- "Natural products play crucial roles in modern drug development and constitute a prolific source of novel lead compounds or pharmacophores for ongoing drug discovery programs. Chemistry and Pharmacology of Naturally Occurring Bioactive Compounds presents cutting-edge research in the chemistry of bioactive natural products and demonstrates how natural product research continues to make significant contributions in the discovery and development of new medicinal entities."--Page  of cover.
- Chemoinformatics 2004, Springer Protocols
- Chemokine receptors 2007, Springer
- Chinese and related North American herbs. 2nd ed. 2009, CRCnetBASEWith the addition of 130 herbs and 100 new references, the second edition provides a basic understanding of the science behind Chinese herbal preparations. Using the same format that made the first edition so popular, author Thomas Li provides a seamless integration of topics drawn from a diverse array of sources. The first table presents major constituents and therapeutic values of more than 1800 species. The data are arranged alphabetically by the Latin name followed by common Chinese and English names. Tables 2 and 3 present data on a total of 700 North American herbs belonging to the same species or genus as Chinese herbs, and a comparison of active ingredients and claimed therapeutic values. Appendices 1, 2, and 3 cross-reference Chinese and scientific names, and major active ingredients and their sources in the Chinese and North American herbs cited in the tables.
- Chirality in drug design and development 2004, CRCnetBASE
- Chitin and chitosan derivatives 2014, CRCnetBASEPart 1. Synthesis and characterization of chitin and chitosan derivatives -- part 2. Biological activities of chitin and chitosan derivatives -- part 3. Biomedical applications of chitin and chitosan derivatives.
- Circadian clocks 2013, SpringerMolecular and cellular basis of circadian clocks -- Molecular components of the mammalian circadian clock / Ethan D. Buhr and Joseph S. Takahashi -- The epigenetic language of circadian clocks / Saurabh Sahar and Paolo Sassone-Corsi -- Peripheral circadian oscillators in mammals / Steven A. Brown and Abdelhalim Azzi -- Cellular mechanisms of circadian pacemaking: beyond transcriptional loops / John S. O'Neill, Elizabeth S. Maywood, and Michael H. Hastings -- The clock in the brain: neurons, glia, and networks in daily rhythms / Emily Slat, G. Mark Freeman Jr., and Erik D. Herzog -- Circadian control of physiology and behavior -- Circadian clocks and metabolism / Biliana Marcheva, Kathryn M. Ramsey, Clara B. Peek, Alison Affinati, Eleonore Maury, and Joseph Bass -- The circadian control of sleep / Simon P. Fisher, Russell G. Foster, and Stuart N. Peirson -- Daily regulation of hormone profiles / Andries Kalsbeek and Eric Fliers -- Circadian clocks and mood-related behaviors / Urs Albrecht -- Chronopharmacology and chronotherapy -- Molecular clocks in pharmacology / Erik S. Musiek and Garret A. FitzGerald -- Cancer chronotherapeutics: experimental, theoretical,and clinical aspects / E. Ortiz-Tudela, A. Mteyrek, A. Ballesta, P.F. Innominato, and F. Lévi -- Pharmacological modulators of the circadian clock as potential therapeutic drugs: focus on genotoxic/anticancer therapy / Marina P. Antoch and Roman V. Kondratov -- Light and the human circadian clock / Till Roenneberg, Thomas Kantermann, Myriam Juda, Ceéline Vetter, and Karla V. Allebrandt -- Systems biology of circadian clocks -- Mathematical modeling in chronobiology / G. Bordyugov, P.O. Westermark, A. Korenčič, S. Bernard, and H. Herzel -- Mammalian circadian clock: the roles of transcriptional repression and delay / Yoichi Minami, Koji L. Ode, and Hiroki R. Ueda -- Genome-wide analyses of circadian systems / Akhilesh B. Reddy -- Proteomic approaches in circadian biology / Maria S. Robles and Matthias Mann.
- Clinical pharmacology of sleep 2006, Springer
- Clinical trials in the neurosciences 2009., Karger
- Co-existence and co-release of classical neurotransmitters 2009, Springer
- Cognitive enhancement 2013, SpringerMedical and Psychosocial Aspects of Cognitive Enhancement --Pharmacological Neuroenhancement: Substances and Epidemiology /Andreas G. Franke, Klaus Lieb --Psychopharmacological Neuroenhancement: Evidence on Safety and Efficacy /Dimitris Repantis --A Bubble of Enthusiasm: How Prevalent Is the Use of Prescription Stimulants for Cognitive Enhancement? /Bradley Partridge --Modeling the Effects of Modafinil on Selective Attention Electroencephalographic Neural Correlates /Carlos Trenado --Behavioral Neuroenhancement /Martin Dresler --The Influence of Sports on Cognitive Task Performance - A Critical Overview /Pavel Dietz --The Human Experiment: How We Won't Win the Rat Race. What Can We Learn from Brain Stimulation in Humans and Rats About Enhancing the Functional Neurobiology of Higher Cognitive Functions? /Colleen A. Dockery --Philosophical and Ethical Aspects of Cognitive Enhancement --Better Brains or Bitter Brains? The Ethics of Neuroenhancement /Kirsten Brukamp --Cognitive Enhancement - To What End? /Michael Hauskeller --Nano-bionic Devices for the Purpose of Cognitive Enhancement: Toward a Preliminary Ethical Framework /Frédéric Gilbert --Cognitive-Enhancing Drugs, Behavioral Training and the Mechanism of Cognitive Enhancement /Emma Peng Chien --What Is Cognitive Enhancement and Is It Justified to Point Out This Kind of Enhancement Within the Ethical Discussion? /Roland Kipke --No Pain, No Gain? Objections to the Use of Cognitive Enhancement on the Basis of Its Potential Effects on the Value of Achievement /Lisa Forsberg --Does the Cognitive Enhancement Debate Call for a Renewal of the Deliberative Role of Bioethics? /Cynthia Forlini, Eric Racine --Sociological, Political and Legal Aspects of Cognitive Enhancement --The Biopolitics of Cognitive Enhancement /Peter B. Reiner --Are We Heading Towards an 'Enhancement Society'? /Armin Grunwald --Leveling the Playing Field: Fairness in the Cognitive Enhancement Debate /Greta Wagner --My Mind Is Mine!? Cognitive Liberty as a Legal Concept /Jan-Christoph Bublitz --Cognitive Enhancement and Criminal Behavior /Elizabeth Shaw --Enhanced Control and Criminal Responsibility /John Danaher.
- Colloids in drug delivery 2010, CRCnetBASESurfactants and block copolymers in drug delivery / Ambikanandan Misra ... [et al.] -- Application of colloidal properties in drug delivery / Swarnlata Saraf -- Polymeric nanocapsules for drug delivery : an overview / Sílvia S. Guterres ... [et al.] -- Poly(alkyl cyanoacrylate) nanoparticles for drug delivery and vaccine development / Anja Graf, Karen Krauel-Göllner, Thomas Rades -- Stimuli-sensitive polymer gels for dermal and transdermal drug delivery and their application in the development of smart textile materials / Witold Musial and Vanja Kokol -- Micelles : the multifunctional nanocarrier for colloidal drug delivery / Chandana Mohanty, Sarbari Acharya, and Sanjeeb K. Sahoo -- Multiple emulsions : an overview and pharmaceutical applications / Jatin Khurana, Somnath Singh, and Alekha K. Dash -- Pharmaceutical and biotechnological applications of multiple emulsions / Rita Cortesi and Elisabetta Esposito -- Nanoemulsions as drug delivery systems / Figen Tirnaksiz, Seyda Akkus, and Nevin Celebi -- Microemulsion systems : application in delivery of poorly soluble drugs / Ljiljana Djekic and Marija Primorac -- Diclofenac solubilization in mixed nonionic surfactants microemulsions / Monzer Fanun -- Self-emulsifying drug delivery systems / D. P. Maurya, Yasmin Sultana, and M. Abul Kalam -- Liquid crystals and their application in the field of drug delivery / Rakesh Patel and Tanmay N. Patel -- Liquid crystalline nanoparticles as drug nanocarriers / Anan Yaghmur and Michael Rappolt -- Niosomal delivery system for macromolecular drugs / Yongzhuo Huang, Faquan Yu, and Wenquan Liang -- A new class of mesoscopic aggregates as a novel drug delivery system / Federico Bordi, Cesare Cametti, and Simona Sennato -- Liposomes and biomacromolecules : effects of preparation protocol on in vitro activity / Paola Luciani, Debora Berti, and Piero Baglioni -- Colloidal nanocarrier systems as a tool for improving antimycobacterial and antitumor activities and reducing the toxicity of usnic acid / N. S. Santos-Magalhães ... [et al.] -- Dendrimers in drug delivery / Hu Yang -- Microsphere : a novel drug delivery system / Abdus Samad ... [et al.] -- Colloids in aerosol drug delivery system / Nazrul Islam -- Respiratory aerosol dynamics with applications to pharmaceutical drug delivery / Jinxiang Xi, P. Worth Longest, and Paula J. Anderson -- Colloidal carriers for drug delivery in dental tissue engineering / Nader Kalaji, Nida Sheibat-Othman, and Hatem Fessi -- Classification and application of colloidal drug delivery systems : passive or active tumor targeting / H. Yesim Karasulu, Burcak Karaca, and Ercüment Karasulu -- Nanocarriers for imaging applications / Vandana Patravale and Medha Joshi.
- Color atlas of pharmacology. 4th ed. 2011, Thieme Book
- Combating fungal infections 2010, Springer"Presents recent research developments to aid fighting fungal infections The currently available means of combating fungal infections are still weak and clumsy. The application of fungal genomics offers an unparalleled opportunity to develop novel antifungal drugs. Interestingly, several novel antifungal drug targets have already been identified and validated. However, it is too early to expect any novel antifungal drug as drug discovery programs are still in their infancy. In addition to classical and genomic approaches to drug discovery, traditional knowledge derived from natural products and phytomedicine can provide a multitude of alternative modes of combating fungal infection. This book comprises 20 chapters on various aspects pertaining to fungal diseases in human and animals, their reservoir, fungal pathogenesis, their management and recent advances in their treatment. Issues of antifungal drug toxicity, especially nephrotoxicity, are also discussed. The development of resistance in fungal pathogens, including multidrug resistance and its mechanism, is dealt with in two chapters. Diverse diagnostic approaches to fungal infections are also reviewed. The combinational drug strategies used in combating invasive fungal infections are addressed in detail. The management of pulmonary mycoses in stem cell transplantation is also given special focus. Novel antifungal drugs (synthetic and herbal), fungal vaccines, and metabolic pathways as drug targets are discussed in detail in three different chapters. Subsequently the roles of innate immunity, cytokine therapy and immunomodulators in the treatment of fungal infections are elaborated upon. As novel drug delivery systems have a great potential for modifying the pharmacokinetics of medications, the last chapter takes this fact into consideration in its examination of state-of-the-art delivery systems in controlling fungal infections."--Publisher's website.
- Comparative and veterinary pharmacology 2010, SpringerThis volume addresses not only a series of key topics in the discipline of veterinary pharmacology and therapeutics that will be of interest to those researching and treating animal disease, but also emphasising the comparative aspects of the subject and the interface with human health and disease.
- Comprehensive medicinal chemistry II 2007, ScienceDirectv. 1. Global perspective / volume editor, Peter D. Kennewell -- v. 2. Strategy and drug research / volume editor, Walter H. Moos -- v. 3. Drug discovery technologies / volume editor, Hugo Kubinyi -- v. 4. Computer-assisted drug design / volume editor, Jonathan S. Mason -- v. 5. ADME-Tox approaches / volume editors, Bernard Testa and Han van de Waterbeemd -- v. 6. Therapeutics areas I: central nervous system, pain, metabolic syndrome, urology, gastrointestinal and cardiovascular / volume editor, Michael Williams -- v. 7. Therapeutic areas II: cancer, infectious diseases, inflammation & immunology and dermatology / volume editors, Jacob J. Plattner & Manoj C. Desai -- v. 8. Case histories and cumulative subject index / volume editors, John B. Taylor & David J. Triggle.
- Computational chemogenomics 2013, CRCnetBASEThis book focuses on applications of compound library design and virtual screening to expand the bioactive chemical space, to target hopping of chemotypes to identify synergies within related drug discovery projects or to repurpose known drugs, to propose mechanism of action of compounds, or to identify off-target effects by cross-reactivity analysis. Both ligand-based and structure-based in silico approaches, as reviewed in this book, play important roles for all these applications. Computational chemogenomics is expected to increase the quality and productivity of drug discovery and lead.
- Computational pharmacokinetics 2008, CRCnetBASEEmpirical pharmacokinetics -- Numerical methods for PK parameter estimation -- Physiological aspects on pharmacokinetics -- Modelling the distribution process -- PK/PD modelling.
- Contract research and development organizations 2011, Springer
- Cyclooxygenases 2008, Springer ProtocolsPart I. In vitro protocols for studying expression and activity of cyclooxygenase enzymes and characterisation of their inhibition patterns -- 1. In vitro cyclo-oxygenase expression and activity protocols : introduction to Part I / Roderick J. Flower -- 2. Techniques used to study regulation of cyclooxygenase-2 promoter sites / Hiroyasu Inoue and Rieko Nakata -- 3. Purification of recombinant human COX-1 and COX-2 / James K. Gierse -- 4. Cloning and expression of cyclooxygenase-1 and cyclooxygenase-2 / Nicholas R. Staten and Beverly A. Reitz -- 5. Expression of cyclooxygenase isoforms in the baculovirus expression system / John C. Hunter, Natalie M. Myres, and Daniel L. Simmons -- 6. Peroxidase active site activity assay / Kelsey C. Duggan, Joel Musee, and Lawrence J. Marnett -- 7. Study of inhibitors of the PGH synthases for which potency Is regulated by the redox state of the enzymes / Olivier Boutaud and John A. Oates -- 8. Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitors / Stefan Laufer and Sabine Luik -- 9. In vitro cyclooxygenase activity assay in tissue homogenates / Samir S. Ayoub -- 10. Techniques used to characterize the binding of cyclooxygenase Inhibitors to the cyclooxygenase active site / William F. Hood -- 11. In vitro Assays for cyclooxygenase activity and inhibitor characterization / Mark C. Walker and James K. Gierse -- -- Part II. Extraction and measurement of prostanoids and isoprostanes -- 12. Extraction and measurement of prostanoids and isoprostanes : introduction to Part II / Paola Patrignani -- 13. Prostanoid extraction and measurement / Lorenzo Polenzani and Samir S. Ayoub -- 14. Measurement of 8-iso-prostaglandin F2a in biological fluids as a measure of lipid peroxidation / Stefania Tacconelli, Marta L. Capone, and Paola Patrignani -- -- Part III. In vivo models to study involvement of cyclooxygenase products in health and disease -- 15. In vivo models to study cyclooxygenase products in health and disease: introduction to Part III / Derek W. Gilroy, Melanie Stables, and Justine Newson -- 16. Protocols to assess the gastrointestinal side effects resulting from inhibition of Cyclo-Oxygenase isoforms / Brendan J.R. Whittle -- 17. Cyclooxygenase enzymes and their products in the carrageenan-induced pleurisy in rats / Adrian R. Moore, Samir S. Ayoub, and Michael P. Seed -- 18. Iloprost-induced nociception : determination of the site of anti-nociceptive action of cyclooxygenase inhibitors and the Involvement of cyclooxygenase products in central mechanisms of nociception / Samir S. Ayoub and Regina M. Botting.
- Dermal absorption models in toxicology and pharmacology 2005, CRCnetBASE
- Desk reference of clinical pharmacology. 2nd ed. 2008, CRCnetBASEThe pharmacokinetic basis of therapeutics -- The pharmacodynamic basis of therapeutics -- Adverse reactions and drug-drug interactions -- Herb-drug interactions -- Food-drug interactions.
- Development of antibody-based therapeutics 2012, Springer1.Translational Strategies for Development of Antibody-Based Therapeutics: An Overview /Mohammad Tabrizi, Gadi Gazit Bornstein and Scott L. Klakamp --2.Discovery Process for Antibody-Based Therapeutics /Heather H. Shih --3.Technologies for the Generation of Human Antibodies /Ramesh R. Bhatt, John S. Haurum and C. Geoffrey Davis --4.Application of Antibody Engineering in the Development of Next Generation Antibody-Based Therapeutics /Randall J. Brezski and Juan Carlos Almagro --5.Biophysical Considerations for Development of Antibody-Based Therapeutics /Andrew W. Drake and Giuseppe A. Papalia --6.Considerations in Establishing Affinity Design Goals for Development of Antibody-Based Therapeutics /Mohammad Tabrizi --7.Bioanalytical Considerations for Development of Antibody-Based Therapeutics: Pharmacokinetics and Immunogenicity /Cherryl B. Funelas and Scott L. Klakamp --8.Preclinical Considerations for Development of Antibody-Based Therapeutics in Oncology /Gregory Landes and Kathleen Elias --9.Factors Impacting the Tumor Localization and Distribution of Antibody-Based Therapeutics in Oncology /David C. Blakey --10.Preclinical Safety Considerations for the Development of Antibody-Based Therapeutics /Lolke de Haan --11.Application of Pharmacokinetic/Pharmacodynamic Modeling in the Development of Antibody-Based Therapeutics /Donald E. Mager --12.Application of Population Pharmacokinetic-Pharmacodynamic Approaches in the Design of Translational Strategies for Development of Antibody-Based Therapeutics /Feng Jin --13.Translational Biomarkers: Essential Tools in Development of Antibody-Based Therapeutics /Mohammad A. Tabrizi and Cherryl B. Funelas --14.Translational Research in Alzheimer's Disease for Development of Antibody-Based Therapeutics /Eric C. Yuen, Enchi Liu and Gene G. Kinney --15.Considerations in Manufacturing Process Development for Antibody-Based Therapeutics /Paula C. Miller and Peiling Xu --16.Strategies for Development of Next Generation Antibody-Based Therapeutics /Mohammad Tabrizi and Gadi Gazit Bornstein --17.Immune Complex Therapies for Treatment of Immune Thrombocytopenia /Rong Deng and Joseph P. Balthasar --18.Application of Bioinformatics Principles for Target Evaluation /Anthony Carvalloza, Mohammad Fallahi and Sahba Tabrizifard --19.Concluding Remarks /Mohammad Tabrizi, Gadi Gazit Bornstein and Scott L. Klakamp.
- Development of novel vaccines 2012, Springer
- Diabetes 2011, SpringerTargeting type 2 diabetes -- Dual acting and pan-PPAR activators as potential anti-diabetic therapies -- GLP-1 agonists and dipeptidyl-peptidase IV inhibitors -- Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes -- SGLT inhibitors as new therapeutic tools in the treatment of diabetes -- Inhibitors of 11[beta]-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy -- Nampt and its potential role in inflammation and type 2 diabetes -- Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance -- Overcoming insulin resistance with ciliary neurotrophic factor -- Thermogenesis and related metabolic targets in anti-diabetic therapy -- Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes -- Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes -- AMP-activated protein kinase and metabolic control -- Mitochondria as potential targets in antidiabetic therapy -- Research and development of glucokinase activators for diabetes therapy : theoretical and practical aspects.
- DNA topoisomerases and cancer 2012, SpringerIntroduction and historical perspective / Patrick Forterre -- Human DNA topoisomerase I : structure, enzymology and biology / James J. Champoux -- Mitochondrial topoisomerases / Ilaria Dalla Rosa, Yves Pommier, and Hongliang Zhang -- Structure and mechanism of eukaryotic type IIA topoisomerases / James M. Berger and Neil Osheroff -- Essential functions of topoisomerase III-alpha in the nucleus and mitochondria / Stefanie Hartman Chen, Jianhong Wu, and Tao-shih Hsieh -- DNA topoisomerase I and illegitimate recombination / Céline Auzanneau and Philippe Pourquier -- Topoisomerase-induced DNA damage / Yves Pommier and Neil Osheroff -- Topoisomerases and carcinogenesis : topoisomerases III-alpha and BLM / Mounira Amor-Guéret and Jean-François Riou -- Topoisomerases inhibitors : a paradigm for interfacial inhibition / Christophe Marchand and Yves Pommier -- Topoisomerases I inhibitors : chemical biology / Beverly A. Teicher -- Topoisomerases II inhibitors : chemical biology / Anna Rogojina ... [et al.] -- Topoisomerases I inhibitors : current use and prospects / Yan Makeyev ... [et al.] -- Topoisomerases II inhibitors : current use and prospects / Olivier Mir ... [et al.] -- Transcriptional stress by camptothecin : mechanisms and implications for the drug antitumor activity / Giovanni Capranico ... [et al.] -- Mechanisms regulating cellular responses to DNA topoisomerases I-targeted agents / Piero Benedetti and Mary-Ann Bjornsti -- Tyrosyl-DNA-phosphodiesterase / Thomas S. Dexheimer ... [et al.] -- Ubiquitin and ubiquitin-like proteins in repair of topoisomerases-mediated DNA damage / Shyamal D. Desai -- Repair of topoisomerases II-mediated DNA damage : fixing DNA damage arising from a protein covalently trapped on DNA / John L. Nitiss ... [et al.] -- Topoisomerases and apoptosis / Olivier Sordet and Stéphanie Solier.
- Dopamine 2005, ScienceDirect
- Dopamine receptors. 2nd ed. 2010, Springer
- Dose finding by the continual reassessment method 2011, CRCnetBASEPart I. Fundamentals -- Chapter 1. Introduction -- Chapter 2. Dose Finding in Clinical Trials -- Chapter 3. The Continual Reassessment Method -- Chapter 4. One-Parameter Dose-Toxicity Models -- Chapter 5. Theoretical Properties -- Chapter 6. Empirical Properties -- Part II. Design Calibration -- Chapter 7. Specifications of a CRM Design -- Chapter 8. Initial Guesses of Toxicity Probabilities -- Chapter 9. Least Informative Normal Prior -- Chapter 10. Initial Design -- Part III. CRM and Beyond -- Chapter 11. The Time-to-Event CRM -- Chapter 12. CRM with Multiparameter Models -- Chapter 13. When the CRM Fails -- Chapter 14. Stochastic Approximation.
- Drug absorption studies 2008, Springer
- Drug and biological development 2007, Springer
- 3D cell-based biosensors in drug discovery programs — Drug and biological development (100)
- Drug delivery systems — Microdialysis in drug development (100)
- Modern anesthetics — Razoxane and dexrazoxane (100)
- Reducing mortality in the perioperative period — What your patients need to know about psychiatric medications (37)
- Harrison's Principles of Internal Medicine
- AAP Red Book Online
- Robbins & Cotran Pathologic Basis of Disease
- Sabiston Textbook of Surgery
- Nelson's Textbook of Pediatrics
- Surgical Exposures in Orthopaedics
- Mandell, Douglas, & Bennett's Principles & Practice of Infectious Diseases
- Red Book Online
- ICU Book
- Primary Care Medicine
- Campbell-Walsh Urology
Shortcut to Licensed Content
Bookmark on other websites
- Select "Add to Favorites" (click “Continue” if you see a security alert)
- From the "Create in" menu, select “Links” (IE7) or “Favorites Bar” (IE8, IE9) to install
- Once installed it will look like this
- Click "Bookmark on Lane" to bookmark any webpage
- Your saved bookmark will appear on this page
What is it?
This shortcut (Lane proxy bookmarklet) gives you access to resources licensed by the library even when you're not coming from a Lane or a Stanford IP address.
While we'd like Lane to be your gateway to our licensed content, we recognize that links to books, articles and journals come from a variety of different sources (Google, your email, RSS reader, etc.).
When installed, it will look your browser bookmark.
At the page you would like to proxy, click the "Lane Gateway to Licensed Content" to invoke it.
If Lane licenses that content, you'll get access as if you were on campus.
How does it work?
This allows you to view the URL as though you were on campus, giving you access to materials licensed for use by the Stanford academic community.
If you're not authenticated, you'll be prompted for your SUNetID and password.
Don't see the Toolbar, Bookmarks, or Links or Favorites bar?
From the "View" menu, select "Toolbars" & choose "Bookmarks Toolbar"
From the "View" menu, choose "Show Bookmarks Bar"
From the "View" menu, choose "Always Show Bookmarks Bar"
- Right-click in a clear area near the browser address bar
- In the menu, check a box next "Links" (IE7) or "Favorites" (IE8, IE9)
- Managing IE Favorites
This shortcut (Lane proxy bookmarklet) only works with resources Lane has licensed and configured to work with our proxy server.
If invoked on a resource we do not license and/or have not yet configured, you will see an error message:
The Lane proxy server cannot complete your request because this host has not been configured properly.
We make no attempt to configure our proxy server for every resource, only those we license and for which a Stanford IP address grants access.
Drag this button onto your browser toolbar to install.
- Right click this button
- Select "Add to Favorites", click "Continue" if you see a security alert
- In "Create in" menu, select "Links" (IE7) or "Favorites Bar" (IE8, IE9) to install
Drag this button onto Safari Bookmarks bar to install.
- Springer Protocols
- MD Consult
- Lange Series
- National Academy Press
- NCBI Bookshelf
- Thieme Atlases